Nuo and Nord CEO: Huge potential in global weight loss market

Novo Nordisk CEO Mike Doustdar said in an interview that pharmaceutical companies are just scratching the surface in developing the global weight loss market, and that companies should focus on expanding access to medications. The head of the company, which launched Wegovy and Ozempic, said that there are 110 million obese people in the United States, but pharmaceutical companies currently only serve 10% to 15% of them. The demand to expand access to medications is also one of the reasons Novo Nordisk agreed to lower drug prices on the prescription drug website TrumpRx for President Trump. Novo Nordisk also plans to reduce the wholesale price of Wegovy by 50% and Ozempic by 35% starting in January next year.